The University of Chicago Header Logo

Connection

Yusuke Nakamura to Hepatitis C, Chronic

Back to Details
This is a "connection" page, showing publications Yusuke Nakamura has written about Hepatitis C, Chronic.
Yusuke Nakamura
Connection Strength
1.419
Hepatitis C, Chronic
  1. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. PLoS One. 2013; 8(12):e84226.
    View in: PubMed
    Score: 0.105
  2. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C. J Gen Virol. 2013 Jan; 94(Pt 1):81-89.
    View in: PubMed
    Score: 0.096
  3. Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. J Infect Dis. 2012 Jan 15; 205(2):204-10.
    View in: PubMed
    Score: 0.091
  4. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol. 2011 Sep; 83(9):1597-607.
    View in: PubMed
    Score: 0.089
  5. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet. 2011 Jul 03; 43(8):797-800.
    View in: PubMed
    Score: 0.088
  6. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2011 Jun; 83(6):981-8.
    View in: PubMed
    Score: 0.088
  7. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011 Jun; 83(6):1048-57.
    View in: PubMed
    Score: 0.088
  8. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011 May; 43(5):455-8.
    View in: PubMed
    Score: 0.087
  9. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011 Jun; 54(6):1094-101.
    View in: PubMed
    Score: 0.086
  10. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011 Feb; 53(2):415-21.
    View in: PubMed
    Score: 0.086
  11. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol. 2011 May; 92(Pt 5):1071-1081.
    View in: PubMed
    Score: 0.085
  12. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011 Feb; 60(2):261-7.
    View in: PubMed
    Score: 0.084
  13. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011 Mar; 54(3):408-14.
    View in: PubMed
    Score: 0.084
  14. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010 Aug; 52(2):421-9.
    View in: PubMed
    Score: 0.083
  15. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010 Sep; 53(3):439-43.
    View in: PubMed
    Score: 0.082
  16. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology. 2009 May; 136(5):1796-805.e6.
    View in: PubMed
    Score: 0.075
  17. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011 Sep 02; 54(3):764-71.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.